Glaukos Co. (NYSE:GKOS) Receives $130.45 Average PT from Analysts

Glaukos Co. (NYSE:GKOS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $134.55.

A number of research firms have issued reports on GKOS. Citigroup lowered shares of Glaukos from a "buy" rating to a "neutral" rating and boosted their target price for the company from $130.00 to $132.00 in a research note on Wednesday, July 10th. BTIG Research boosted their target price on shares of Glaukos from $131.00 to $139.00 and gave the company a "buy" rating in a research note on Wednesday, August 28th. Piper Sandler set a $140.00 target price on shares of Glaukos in a research note on Thursday, October 17th. Morgan Stanley boosted their target price on shares of Glaukos from $100.00 to $120.00 and gave the company an "equal weight" rating in a research note on Monday, July 15th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday.

Glaukos Price Performance

Shares of GKOS traded down $3.69 during mid-day trading on Tuesday, reaching $127.69. 1,672,744 shares of the company's stock were exchanged, compared to its average volume of 576,013. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. The company has a 50-day simple moving average of $129.48 and a two-hundred day simple moving average of $120.20. Glaukos has a 52-week low of $59.22 and a 52-week high of $139.51. The company has a market cap of $7.02 billion, a price-to-earnings ratio of -39.17 and a beta of 1.02.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to analysts' expectations of $91.50 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. Glaukos's revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.50) EPS. On average, sell-side analysts predict that Glaukos will post -2.16 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the transaction, the director now owns 30,119 shares in the company, valued at approximately $3,614,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Glaukos news, Director Marc Stapley sold 6,250 shares of the firm's stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the sale, the director now owns 34,076 shares in the company, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Aimee S. Weisner sold 25,000 shares of the firm's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares of the company's stock, valued at $3,614,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 41,525 shares of company stock valued at $5,142,029 in the last ninety days. Company insiders own 6.40% of the company's stock.

Institutional Investors Weigh In On Glaukos

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Values First Advisors Inc. bought a new position in shares of Glaukos in the 3rd quarter valued at about $25,000. GAMMA Investing LLC boosted its stake in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock valued at $141,000 after purchasing an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC bought a new position in shares of Glaukos in the 2nd quarter valued at about $187,000. Brighton Jones LLC bought a new position in shares of Glaukos in the 2nd quarter valued at about $208,000. Finally, Procyon Advisors LLC bought a new position in shares of Glaukos in the 3rd quarter valued at about $210,000. Institutional investors and hedge funds own 99.04% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.